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Predominant or codominant immunoglobulin (Ig) A deposition in the glomerular mesangium characterizes IgA nephropathy
(IgAN). Accumulated glomerular IgA is limited to the IgA1 subclass and usually galactose-deﬁcient. This underglycosylated IgA
may play an important role in the pathogenesis of IgAN. Recently, antibodies against galactose-deﬁcient IgA1 were found to be
well associatedwith thedevelopment of IgAN. Severaltherapeutic strategies based on corticosteroids or otherimmunosuppressive
agents have been shown to at least partially suppress the progression of IgAN. On the other hand, several case reports of kidney
transplantation or acquired IgA deﬁciency uncovered a remarkable ability of human kidney to remove mesangial IgA deposition,
resulting in the long-term stabilization of kidney function. Continuous exposure to circulating immune complexes containing
aberrantly glycosylated IgA1 and sequential immune response seems to be essential in the disease progression of IgAN. Removal
of mesangial IgA deposition may be a challenging, but fundamental approach in the treatment of IgAN.
1.Introduction
SinceIgAnephropathy(IgAN)wasﬁrstlydescribedbyBerger
and Hinglais in 1968 [1], IgAN is regarded one of the
most common forms of glomerulonephritis worldwide [2].
Because 30 to 40% of IgAN patients reach end-stage kidney
disease within 20 years [2, 3], it is critical to clarify the
true pathogenesis. Clinical onset of IgAN is probably more
common in the second and third decades of life [4–7]. This
disease is more common in men, but reported male-female
ratios were ranging from less than 2:1 in Japan to as high
as 6:1 in the United States and northern Europe. Although
I g A No c c u r si na l le t h n i cg r o u p s ,t h er e a s o nw h yw h i t e s
and Asians are more prone to IgAN than are blacks remains
unclear [8, 9]. Approximately 50% of newly diagnosed
glomerulonephritis in Japan is due to IgAN, though much
lower rates are reported in the United States and Western
Europe [3].Althoughthereseemstobetrueracialdiﬀerences
due to a genetic predisposition to IgAN, the diﬀerences in
kidneybiopsypracticesmayalsoreﬂectthesedisparities[10].
IgAN is characterized by predominant or codominant
IgA deposits in the glomerular mesangium, but many other
diseases including Henoch-Sch¨ onlein purpura nephritis
(HSPN) are also associated with glomerular IgA deposits
[10]. Now, IgAN and HSPN are recognized to be related
diseases since both can be encountered consecutively in
the same patient, are found in identical twins, and bear
identical pathological and biological abnormalities [10].
Recent studies strongly suggest that aberrant glycosylation of
the O-linked glycans in IgA1 hinge region is an important
common pathogenic factor contributing to the development
of IgAN [10–14]a n dH S P N[ 15, 16]. Galactose-deﬁcient
IgA1 is recognized by naturally occurring IgG or IgA1
antibodies resulting in formation of immune complexes
[13]. The circulating immune complexes thus formed have
a tendency to accumulate in glomerular mesangium and are2 Clinical and Developmental Immunology
considered as a main cause of glomerular injury, though the
entire pathogenesisof these diseases remains still unresolved.
Herein, we review the recent development of basic and
clinical investigations in IgAN and also refer to an approach
aiming at IgA removal as a future therapeutic potential.
2.Pathogenesisof AberrantlyGlycosylated
IgA1 in IgAN
IgANisthediseaseofglomerularIgAdeposition.Glomerular
deposition of IgA requires several potential mechanisms
including increased production of IgA in bone marrow,
decreased clearance of IgA, and binding of IgA to mesangial
cells[10];however,thetruepathogenesishasnotbeenclearly
deﬁned. Recent data suggest that aberrant glycosylation of
the O-linked glycans in IgA1 hinge region is a key factor
in the development of IgAN. Because deposited IgA in the
mesangium is restricted toIgA1subclass [11,12],researchers
had so far attempted to clarify the qualitative or quantitative
aspects of IgA1 abnormalities in IgAN.
Increased production of IgA1 in the bone marrow is
thought to be responsible for the elevation of serum IgA1
[19, 20]; however, IgA-producing myeloma is usually unac-
companied by IgAN, and only the patients with aberrantly
glycosylated IgA1 develop glomerulonephritis in cases with
IgA1 multiple myeloma [21, 22]. Therefore, the qualitative
abnormality of IgA molecules is now recognized as a
fundamental cause of developing IgAN.
Unlike IgA2 and other immunoglobulins, IgA1 has a
uniquestructureofmultipleO-glycosylation sitesinitshinge
region. Although O-linked glycans in the hinge region in
healthy individuals are composed of N-acetylgalactosamine
with β1,3 linked galactose, a majority of the IgA1 in the
glomerular deposits in patients with IgAN is galactose-
deﬁcient.This aberrantlyglycosylatedIgA1isalsodetectedin
sera and in circulating immune complexes in IgAN patients,
while it is rarely found in healthy controls [10–14]. The
similar abnormality in IgA1 glycosylation has been also
conﬁrmed in HSPN [15, 16].
The synthesis of the O-glycans in human IgA1 hinge
regions is initiated by the addition of N-acetylgalactosamine
(GalNAc) to serine or threonine residues through the
activity of UDP-N-acetyl-alpha-D-galactosamine (especially,
pp-GalNAc-T2) [23]. The O-glycan chain is then extended
by sequential attachment of galactose and sialic acid
residues to GalNAc. Galactose is attached to GalNAc by
core 1 β1,3-galactosyltransferase (C1GalT1) coordinated
with its chaperone of core-1-β3-Gal-T speciﬁc molecu-
lar chaperone (Cosmc) [24–26], and also sialic acid (N-
acetylneuraminic acid, NeuNAc) is attached to GalNAc by
α2,6-GalNAc-sialyltransferase2 (ST6GalNAc2) [17]. There-
fore, one can hypothesize that the imbalance in the activities
ofC1GalT1/Cosmc and ST6GalNAc2[10, 18]canc on tribut e
to the undergalactosylation of IgA1 in IgAN. Results from
a recent in vitro study by Suzuki et al. supported this
hypothesis [27]. They demonstrated the C1GalT1 activity
was signiﬁcantly lower, while the ST6GalNAc2 activity
was signiﬁcantly higher in EBV-immortalized IgA-secreting
lymphocytes from patients with IgAN. Indeed, a more recent
analysis showed that the speciﬁc haplotype combinations
in C1GalT1 and ST6GalNAc2 were well associated with a
predisposition for IgAN and renal outcomes [28]. However,
it remains controversial whether the undergalactosylation
of IgA1 is a direct consequence of functional changes in
C1GALT1/Cosmc or ST6GalNAc2activities [14]. In addition
to the two glycosyltransferase genes, various genes such as
6.5-cM region, IGAN1, in 6q22-23, and another region in
chromosome 2q36 have been identiﬁed as disease-related
factors in IgAN. However, the exact roles of these genetic
regions in the pathogenesis of IgAN still remain to be
clariﬁed [29, 30].
Higher levels of serum galactose-deﬁcient IgA1 in
patients with IgAN and their relatives than in healthy
controls rather support a genetic predisposition of aberrant
IgA glycosylation [31]. The observed inheritance pattern of
galactose-deﬁcient IgA1 levels might suggest an autosomal
dominant transmission. Because relatives with higher serum
levels of aberrantly glycosylated IgA1 were mostly asymp-
tomatic, additional cofactors other than the aberrant IgA
glycosylation may be required for the development of IgAN
[31].
While galactose-deﬁcient IgA1 alone is insuﬃcient to
produce IgAN, the IgG antibodies and IgA1 antibodies
may also play an important role in the pathogenesis of
IgAN by forming circulating immune complexes contain-
ing aberrantly glycosylated IgA1 [13]. Galactose-deﬁcient
IgA1 molecules are recognized by glycan-speciﬁc IgG or
IgA1 antibodies, and IgA1-containing immune complexes
are formed [32, 33]. Then, galactose-deﬁcient IgA1, as a
component of the large immune complexes, may easily
escape hepatic catabolism and have a longer life-span than
normal IgA1[34].DepositedIgA1may,inturn,inducemany
kinds of inﬂammatory mediators. Cytokines and growth
factors, such as interleukin-6 [35, 36], transforming growth
factor β1[ 37–39], and platelet-derived growth factor [40]i n
sera of patients with IgAN were associated with mesangial
proliferation or tubulointerstitial ﬁbrosis.
Thesemesangial cellsproliferationandglomerularinjury
may be induced by circulating immune complexes, in par-
ticular, containing aberrantly glycosylated IgA1. A recent in
vitro study demonstrated that the circulating immune com-
plexes containing galactose-deﬁcient IgA1 prepared from
sera of IgAN patients stimulated mesangial cell prolifera-
tion more eﬃciently than uncomplexed IgA1 or immune
complexes prepared from healthy control subjects [13]. This
stimulatory activity was lost in fractions devoid of IgA1.
Indeed, circulating immune complexes containing higher
levels of galactose-deﬁcient IgA1 enhanced mesangial cell
proliferation more eﬃciently than complexes with lower
levelsofgalactose-deﬁcientIgA1[13].Anotherrecentin vitro
study, using subcloned EBV-immortalized B cells from IgAN
patients and healthy controls, revealed that the elevation in
serum levels of antibodies against galactose-deﬁcient IgA1 is
well associated with the development of IgAN [41]. These
ﬁndings strongly suggest that circulating immune complexes
containing aberrantly glycosylated IgA1, by accumulating
in glomerular mesangium in patients with IgAN, may playClinical and Developmental Immunology 3
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Figure 1: The galactose-deﬁcient IgA1 molecule and the immunecomplexes formationin the pathogenesis of IgAN. IgA1 has characteristic
hinge regions between the CH1 and CH2 domains (CH, the constant regions of the heavy chain), which contain at least six serine (Ser) or
threonine (Thr) residues as O-linked glycosylation sites. In the ﬁrst step, the enzyme polypeptide N-acetylgalactosaminyltransferase (pp-
GalNAc-T2) facilitates the attachment of N-acetylgalactosamine (GalNAc) to these residues. In the second step, the IgA1 glycosylation
is extended in two ways. One is the binding of N-acetylneuraminic acid (NeuNAc) to GalNAc through the action of the enzyme N-
acetylgalactosamine-speciﬁc α2,6-sialyltransferas (ST6GalNAc2) [17]. The other is galactose (Gal) connection to GalNAc through the
enzyme core 1 β1,3 galactosyltransferase (C1GalT1) and core-1-β3-Gal-T speciﬁc molecular chaperone (Cosmc) [18]. The imbalance
between those activities may promote galactose-deﬁcient IgA1 production [10, 18]. Galactose-deﬁcient IgA1 is aggregated with antiglycan
IgG or IgA1 antibodies, resulting in formation of immune complexes [13], which may escape the normal catabolism in liver and also
accumulate with high aﬃnity in glomerular mesangium.
pivotal roles in the development and progression of kidney
injury as shown in Figure 1. Further investigations about the
roles of these antibodies are expected to provide new insights
into the pathogenesis of IgAN.
Although alterations in IgA1 glycosylation certainly play
an important role in the progression of kidney disease
in IgAN, serum levels of galactose-deﬁcient IgA1 are not
necessarily elevated in a signiﬁcant proportion of patients
with IgAN [42, 43]. Thus, it should be emphasized that
the abnormality in IgA1 glycosylation may not be the only
mechanism underlying the development of IgAN.
3.RecentClinicalTrialsinTreatmentforIgAN
A randomized controlled trial (RCT) of treatment for IgAN
reported by Pozzi et al. showed a remarkable eﬃcacy of
6-month corticosteroids therapy (intravenous methylpred-
nisolone 1g for 3 days at months 1, 3, and 5, followed
by oral prednisone 0.5mg/kg/alternate-day for 6 months)
[44]. The follow-up analysis of this study showed that the
proportion of patients who reached 50% increase in serum
creatininewassigniﬁcantlylowerinthecorticosteroidsgroup
than in the control group at 10 years after the treatment
[45].Thebeneﬁcialeﬀectsofangiotensin-converting enzyme
inhibitor (ACEi) in the treatment for IgAN were reported
in another RCT by Praga et al. [46]. In this study, while
blood pressure control was similar between the two groups,
the patients who reached the same primary endpoint were
less in the ACEi group than in the control group. Recently,
RCTs by Manno et al. [47]a n dL ve ta l .[ 48]s h o w e d
the additive beneﬁts of corticosteroids on the ACEi-based
therapy. Kidney function, during the each follow-up period,
was more preserved in the combination therapy group than
that in the control group. Decline of estimated glomerular
ﬁltration rate (eGFR) was slower, and more strict control
of proteinuria was achieved in the combination therapy
group than in the ACEi monotherapy group. However, a
recent critical review pointed out that it still remained
controversialwhethercorticosteroidsshouldbeadministered
in IgAN patients who were already treated with maximum
recommended dose of ACEi [49]. Indeed, more aggressive
immunosuppressive therapy should be undertaken carefully.
A recent RCT failed to demonstrate the additional beneﬁt of
low-doseazathioprineaddingtocorticosteroidsfor6months
[50]. Although adverse side eﬀects were more frequent in
the combination therapy group, reduction of proteinuria
and 5-year cumulative kidney survival were comparable
in the combination therapy group and the corticosteroids
monotherapy group. Tang et al. recently reported the eﬃcacy
of mycophenolate mofetil (MMF) in the treatment of IgAN4 Clinical and Developmental Immunology
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Figure 2: Repeated kidney biopsies in an HSPN patient with acquired IgA deﬁciency. (a, b) The ﬁrst kidney biopsy (performed at 7 years
old) showing necrotizing crescentic glomerulonephritis with advanced glomerulosclerosisand severe tubulointerstitial nephritis, which was
compatible with HSPN grade 5b. (c, d) The fourth kidney biopsy (performed at 21 years old) showing minor glomerular abnormalities.
Kidney biopsy samples were stained with periodic acid methenamine silver (a, b, and c), and periodic acid Schiﬀ (d), respectively. Original
magniﬁcationswere ×10 (a, c) and ×40 (b, d), respectively.
[51]. In that study, 40 IgAN patients with persistent pro-
teinuria (>1g/day) despite the conventional treatment with
renin-angiotensin system inhibitors were randomized to the
immunosuppression group receiving MMF for 6 months
or the control group receiving the conventional treatment
alone. They concludedthat MMF provided partial remission
of proteinuria in the ﬁrst 2 years and better kidney survival
at 6 years after the treatment. However, the observational
periods of these and other studies in IgAN, published until
thepresenttime,wererelativelyshortcomparedtothenature
of the slow disease progression of IgAN [44–55]. Thus,
it is not fully established whether these beneﬁcial eﬀects
of immunosuppressive therapies can result in the better
prognosis after the long-term follow-up period. Moreover,
it has not been clear whether such immunosuppressive
therapies are eﬀective even in patients with severe IgAN,
because most of the previous clinical trials were conducted
onIgANpatientswithmildtomoderatekidneyinsuﬃciency.
4.TherapeuticApproachAimingat
IgA Removal
Human kidney has a considerable self-puriﬁcation ability to
remove IgA deposits from glomeruli, because the previous
reports showed that transplanted kidneys from donors
with subclinical IgAN into recipients without IgAN rapidly
cleared the glomerular deposits [56, 57]. This ability may
be altered in IgAN patients. Several studies, focusing on IgA
receptors, showed that IgA1-containing circulating immune
complexes from IgAN patients bind to mesangial cells with
higheraﬃnitythancomplexesfromhealthycontrols[58,59].
Based on the clinical experiences in kidney transplanta-
tion described above, it is also suggested that the continuous
exposure to circulating immune complexes, containing aber-
rantly glycosylated IgA1, and sequential immune responses
may be essential for the disease progression of IgAN. Thus,
the fundamental treatment of IgAN seems to block these
processes.
Recently, Lamm et al. reported a novel therapeutic
potential for IgAN [60]. They demonstrated the ability
of the bacterial IgA protease to remove glomerular IgA
immune complexes in a mouse model of IgAN. Because
of the absence of IgA1 with its hinge region in such
animals, they designed a passive mouse model of IgAN
by injecting immune complexes containing human IgA1.
After the systemically administration of the IgA protease
derived from Haemophilus inﬂuenza,t h em e s a n g i a lI g A
immunoﬂuorescence intensities were signiﬁcantly reduced.
This treatment strategy, targeting the removal of mesangial
IgA1 deposits, is novel and interesting; however, we have
to overcome some limitations of this study for clinicalClinical and Developmental Immunology 5
application in human IgAN. First, there are some diﬀerences
in IgA glycosylation, IgA clearance, and control of IgA
synthesis between rodents and humans. Second, the deposi-
tion and the removal of glomerular IgA-containing immune
complexes in the mice model are too rapid compared to
the much slower processes in human IgAN. Moreover,
the circulating load of IgA1 is substantial and may well
consume the protease before it has any eﬀect in the kidney.
Furthermore, circulating neutralizing antibody may appear
tolessentheimpactofsuchatherapeuticapproach.Finally,it
isunknown whether thesimilar approach is safe andpossible
in human IgAN at present. Further studies are required to
investigatehoweﬃcientlytheIgAprotease digestscirculating
immune complexes and deposited complexes.
We have recently documented a case of HSPN with
acquiredIgAdeﬁciency[61],which maygiveus someclinical
hints about the eﬃcacy of IgA removal. The patient was
initially diagnosed as the severest form of HSPN (grade
5b), according to the criteria of International Study of
Kidney Disease in Children [62] at 7 years old. During
the immunosuppressive therapy, the patient developed virus
associated hemophagocytic syndrome. Interestingly, initially
elevated serum levels of IgA severely decreased after those
events and remained undetectable until the present time.
Although her original clinicopathological ﬁndings rather
suggested a poor prognosis [63], periodic examination, and
repeated kidney biopsies performed over a period of 14
years showed an excellent clinical course consisting of the
normalization of kidney function, the marked reduction in
protenuria, and the remarkable histological improvement as
shown in Figure 2.N os e r i o u sa d v e r s ec l i n i c a ls y m p t o m s
related to IgA deﬁciency were observed.
Unfortunately, we do not know whether this patient had
the aberrantly glycosylated IgA1. However, our case suggests
thatacquiredIgAdeﬁciencyworksfavorablyintheresolution
of severe HSPN.
5.Conclusion
Galactose-deﬁcientglycosylatedIgA1seemstobeakeyfactor
in the pathogenesis of IgAN. Based on the recent stud-
ies, continuous exposure to circulating immune complexes
containing aberrantly glycosylated IgA1 may be essential in
the disease progression of IgAN. While several clinical trials
based on the immunosuppressive agents reported promising
eﬀects, it remains unclear whether such therapies really
improve the long-term prognosis of IgAN.
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